Literature DB >> 21641806

Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma.

Changyan Liang1, Yuebo Yang, You Ling, Yueshan Huang, Tian Li, Xiaomao Li.   

Abstract

Folate (FOL) mediated poly-lactide-co-glycolide-polyethylene glycol nanoparticles (FOL-PEG-PLGA NPs) bearing paclitaxel (PTX) were prepared for the effective delivery of drug to endometrial carcinoma. The average size, zeta potential and encapsulation efficiency of FOL-targeted NPs were found to be around 220 nm, -30.43 mV and 95.6%. Cellular uptake was observed. The accumulation of FOL-targeted NPs depends on dual effects of passive and active targeting. The FOL-targeted PTX NPs showed a greater cytotoxicity against HEC-1A cancer cells in vitro and in vivo, which might be induced by apoptosis. H&E staining did not showed apparent tissue damage to liver and kidney of the mice after injecting NPs intravenously. These results suggest that the novel FOL-PEG-PLGA NPs could be a potential delivery system with excellent therapeutic efficacy for targeting the drugs to cancer cells.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21641806     DOI: 10.1016/j.bmc.2011.05.016

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  18 in total

Review 1.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Authors:  Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad
Journal:  Chem Soc Rev       Date:  2012-03-05       Impact factor: 54.564

Review 2.  Strategies to target tumors using nanodelivery systems based on biodegradable polymers, aspects of intellectual property, and market.

Authors:  Michele F Oliveira; Pedro P G Guimarães; Alinne D M Gomes; Diego Suárez; Rubén D Sinisterra
Journal:  J Chem Biol       Date:  2012-11-30

3.  Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.

Authors:  Feihu Wang; Michael Porter; Alexandros Konstantopoulos; Pengcheng Zhang; Honggang Cui
Journal:  J Control Release       Date:  2017-09-25       Impact factor: 9.776

Review 4.  Current progress in nanotechnology applications for diagnosis and treatment of kidney diseases.

Authors:  Sue Hyun Lee; Jung Bok Lee; Min Soo Bae; Daniel A Balikov; Amy Hwang; Timothy C Boire; Il Keun Kwon; Hak-Joon Sung; Jae Won Yang
Journal:  Adv Healthc Mater       Date:  2015-06-29       Impact factor: 9.933

5.  Shape mediated splenotropic delivery of buparvaquone loaded solid lipid nanoparticles.

Authors:  Heena V Maithania; Bhabani S Mohanty; Pradip R Chaudhari; Abdul Samad; Padma V Devarajan
Journal:  Drug Deliv Transl Res       Date:  2020-02       Impact factor: 4.617

6.  Biomimetic peptide display from a polymeric nanoparticle surface for targeting and antitumor activity to human triple-negative breast cancer cells.

Authors:  Eric M Bressler; Jayoung Kim; Ron B Shmueli; Adam C Mirando; Hojjat Bazzazi; Esak Lee; Aleksander S Popel; Niranjan B Pandey; Jordan J Green
Journal:  J Biomed Mater Res A       Date:  2018-02-23       Impact factor: 4.396

Review 7.  Nanomedicine in chemoradiation.

Authors:  Seth M Miller; Andrew Z Wang
Journal:  Ther Deliv       Date:  2013-02

Review 8.  Targeted delivery system of nanobiomaterials in anticancer therapy: from cells to clinics.

Authors:  Su-Eon Jin; Hyo-Eon Jin; Soon-Sun Hong
Journal:  Biomed Res Int       Date:  2014-02-19       Impact factor: 3.411

9.  Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer.

Authors:  Armando Lucero-Acuña; Justin J Jeffery; Edward R Abril; Raymond B Nagle; Roberto Guzman; Mark D Pagel; Emmanuelle J Meuillet
Journal:  Int J Nanomedicine       Date:  2014-12-03

Review 10.  Targeted therapy using nanotechnology: focus on cancer.

Authors:  Vanna Sanna; Nicolino Pala; Mario Sechi
Journal:  Int J Nanomedicine       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.